Drug Trial Radar · NCT05096832
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study
Last checked: Nov 19, 2026Latest source record: Apr 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10,381
Actual
Start
Nov 3, 2021
Primary completion
Feb 18, 2022
Study completion Apr 14, 2023
Sponsor
- Lead sponsor
- Livzon Pharmaceutical Group Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Global, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older after the Vaccination of 2 Doses of Inactivated Vaccines
Conditions
- COVID-19 Pandemic
Interventions
Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)Biological
Appearance: Creamy white suspension Dosage form: Suspension for injection Strength: 10 μg (0.5 mL) /vial Vaccination route: Intramuscular injection into the lateral deltoid of the upper arm Vaccination dosage: 10 μg (0.5 mL) Immunization schedule: 1 dose on Day 0, which should be 3-6 months after the second dose of 2-dose regimen of inactive vaccine (BBIBP-CorV or CoronaVac). Storage condition: Store at 2-8 °C protected from light Expiry date: 24 months temporarily
Blank Preparation of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)Biological
The dosage, appearance, administration method, and other aspects are consistent with that of investigational vaccine, except that no vaccine antigen is contained.
Primary outcomes
What the sponsor says the trial is designed to measure.
- the relative efficacy of recombinant SARS-CoV-2 fusion protein vaccine (V-01) as a booster to prevent symptomatic and RT-PCR positive COVID-19 (mild or above severity)Time frame: From 15days after the administration of recombinant SARS-CoV-2fusion protein vaccine (V-01) to 12 months after full-courseimmunization
- The incidence of adverse events (AEs)Time frame: Within 28 days after the booster vaccination
Locations
18 sites in 2 countries. Site status is shown where the registry gives one.
Sunway Medical Centre Velocity (SMCV) Cheras
Kuala Lumpur, Malaysia
Hospital Pakar Sultanah Fatimah
Muar town, Malaysia
Sunway Medical Centre (SunMed)
Petaling Jaya, Malaysia
Hospital Pulau Pinang
Pulau Pinang, Malaysia
Klinik Kesihatan Seremban 2
Seremban, Malaysia
Seri Manjung Hospital
Seri Manjung, Malaysia
Hospital Sibu
Sibu, Malaysia
Hospital Sultan Abdul Halim
Sungai Petani, Malaysia
Hospital Taiping
Taiping, Malaysia
Sarawak General Hospital
Kuching, Sarawak, Malaysia
Central Hospital Gujranwala
Gujranwala, Pakistan
Shifa International Hospitals
Islamabad, Pakistan
Aga Khan University Hospital
Karachi, Pakistan
Dow University Hospital
Karachi, Pakistan
Sindh Infectious Diseases Hospital & Research Center
Karachi, Pakistan
Al Khidmat Foundation - Surraya Azeem Waqf Hospital
Lahore, Pakistan
Avicenna Dental College
Lahore, Pakistan
Central Park Medical College and Hospital
Lahore, Pakistan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.